Skip to main content

Table 1 Temporal reproducibility of EDTA plasma biomarkers measured by Luminex xMap™, NSHDS subjects a (n = 18 pairs)

From: Temporal reliability of cytokines and growth factors in EDTA plasma

Biomarker

LLD

First Sample

Second Sample

Intra-batch CV

ICC

(95% CI)

  

% Above LLD

Median

(25%, 75%)

% Above LLD

Median

(25%, 75%)

   

hsIL-1β (pg/mL)b

0.06

100

8.1

(5.5, 11.3)

100

8.0

(4.6, 10.1)

2.0%

0.73

(0.43-0.89)

hsIL-2 (pg/mL)b

0.16

100

28.8

(18.9, 39.1)

100

31.3

(20.8, 39.9)

2.7%

0.80

(0.56-0.92)

sIL-2R (pg/ml)c

30

100

652

(624, 789)

100

691

(624, 762)

1.0%

0.86

(0.68-0.95)

IL-4 (pg/mL)c

5

100

140

(114, 163)

100

120

(109, 143)

1.6%

0.00

(-0.45-0.45)

hsIL-4 (pg/mL)b

0.13

100

50.5

(31.4, 80.7)

100

42.4

(16.2, 83.0)

2.7%

0.70

(0.36-0.87)

hsIL-5 (pg/mL)b

0.01

100

3.4

(1.8, 4.6)

100

3.2

(1.8, 4.2)

2.5%

0.73

(0.41-0.89)

hsIL-6 (pg/mL)b

0.10

100

20.4

(15.9, 28.7)

100

18.4

(13.8, 24.3)

2.0%

0.81

(0.56-0.92)

sIL-6R (ng/mL)c

0.024

100

29.0

(26.5, 42.6)

100

29.8

(25.2, 36.4)

0.3%

0.69

(0.36-0.87)

hsIL-7 (pg/mL)b

0.12

100

10.1

(6.5, 15.7)

94.4

10.7

(6.1, 13.7)

3.3%

0.55

(0.14-0.80)

hsIL-8 (pg/mL)b

0.11

100

9.3

(6.4, 11.8)

100

8.3

(5.3, 10.5)

1.6%

0.86

(0.68-0.95)

hsIL-10 (pg/mL)b

0.15

100

40.7

(26.7, 57.2)

100

33.2

(15.8, 56.3)

2.1%

0.75

(0.46-0.90)

IL-12p40 (pg/mL)c

15

100

410

(379, 471)

100

413

(402, 447)

0.7%

0.89

(0.73-0.96)

hsIL-12p70 (pg/mL)b

0.11

100

32.3

(21.5, 46.5)

100

26.0

(11.8, 40.7)

2.1%

0.77

(0.50-0.91)

hsIL-13 (pg/mL)b

0.48

100

45.7

(30.5, 51.9)

100

39.6

(15.4, 50.2)

3.0%

0.81

(0.56-0.92)

CRP (ÎĽg/mL)b

0.000002

100

10.6

(3.1, 17.1)

100

8.5

(4.0, 16.9)

1.9%

0.76

(0.48-0.90)

IFNα (pg/mL)c

15

100

45.8

(41.1, 70.7)

100

50.2

(37.8, 80.7)

5.1%

0.53

(0.11-0.79)

IFNÎł (pg/mL)c

5

100

175

(108, 199)

100

118

(95.3, 162)

1.8%

0.00

(-0.45-0.45)

hsIFNÎł (pg/mL)b

0.29

100

78.3

(42.6, 99.4)

100

65.0

(43.4, 103)

2.2%

0.72

(0.41-0.89)

hsTNFα (pg/mL)b

0.05

100

8.0

(6.2, 11.2)

100

8.4

(5.8, 10.9)

1.9%

0.69

(0.36-0.87)

sTNF-R1 (ng/mL)c

0.015

100

1.3

(1.2, 1.8)

100

1.2

(0.9, 1.6)

1.7%

0.31

(-0.16-0.67)

sTNF-R2 (ng/mL)c

0.015

100

1.1

(0.72, 1.2)

100

0.9

(0.7, 1.1)

0.5%

0.68

(0.33-0.86)

Growth Factors

          

EGFR (ng/mL)d

0.020

100

15.4

(14.1, 15.9)

100

15.3

(13.9, 16.6)

0.5%

0.93

(0.83-0.97)

ErbB2 (ng/mL)d

0.017

100

3.4

(2.9, 3.6)

100

3.2

(3.0, 3.8)

0.5%

0.63

(0.26-0.84)

hsGM-CSF (pg/mL)b

0.46

100

38.2

(29.6, 52.4)

100

33.5

(21.9, 39.9)

2.9%

0.47

(0.03-0.76)

G-CSF (pg/mL)c

15

100

129

(108, 167)

100

129

(108, 160)

6.4%

0.75

(0.46-0.90)

HGF (pg/mL)c

10

100

151

(101, 186)

100

196

(101, 278)

1.1%

0.74

(0.43-0.89)

  1. Note: LLD = lower limit of detection as reported by the manufacturer, CVs are based on 8 blinded duplicates
  2. a Limited to the biomarkers for which more than 70% of all the samples were detectable. There were no extrapolated values for any of the markers included in the table except for 1 sample for IFNα. Sixteen markers are not included because more than 30% of samples were undetectable (IL-1β, IL-1RA, IL-5, IL-6, IL-17, VEGF), and/or a high percentage of samples were extrapolated below the lowest point on the standard curve (IL-1α, IL-2, IL-7, IL-8, IL-10, IL-13, IL-15, TNFα, EGF, bFGF).
  3. b Kits from Linco/Milliporec Kit from Biosource
  4. d Kit developed in-house
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us